- •Association of high BMI with survival is eliminated when adjusted for confounders.
- •Association of high BMI with survival disappears when adjusted for weight loss.
- •Weight loss in NSCLC and melanoma is the predominant prognostic factor.
- •In patients with NSCLC, reduced skeletal muscle is an independent prognostic factor.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma.J Clin Oncol. 2020; 38: 3937-3946https://doi.org/10.1200/J.20.00995
- Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.Nat Med. 2022; 28: 315-324https://doi.org/10.1038/s41591-021-01655-5
- Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation.Clin Cancer Res. 2019; 25: 946-956https://doi.org/10.1158/1078-0432.CCR-18-0793
- Editorial: pathophysiological interrelationship between obesity, metabolic diseases, and cancer.Front Oncol. 2021; 11755735https://doi.org/10.3389/fonc.2021.755735
- Body fatness and cancer – viewpoint of the IARC working group.N Engl J Med. 2016; 375: 794-798https://doi.org/10.1056/NEJMsr1606602
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.Lancet Oncol. 2018; 19: 310-322https://doi.org/10.1016/S1470-2045(18)30078-0
- The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients.J Immunother cancer. 2019; 7: 222https://doi.org/10.1186/s40425-019-0699-5
- Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.JAMA Oncol. 2020; 6: 512-518https://doi.org/10.1001/jamaoncol.2019.5241
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.J Immunother cancer. 2019; 7: 57https://doi.org/10.1186/s40425-019-0527-y
- The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.Lung Cancer. 2020; 139: 140-145https://doi.org/10.1016/j.lungcan.2019.11.011
- Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study.PLoS One. 2018; 13e0204729https://doi.org/10.1371/journal.pone.0204729
- Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.J Immunother cancer. 2020; 8https://doi.org/10.1136/jitc-2020-001117
- Re-evaluating the effects of obesity on cancer immunotherapy outcomes in renal cancer: what do we really know?.Front Immunol. 2021; 12668494https://doi.org/10.3389/fimmu.2021.668494
- Diagnostic criteria for the classification of cancer-associated weight loss.J Clin Oncol. 2015; 33: 90-99https://doi.org/10.1200/JCO.2014.56.1894
- Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.J Clin Oncol. 2013; 31: 1539-1547https://doi.org/10.1200/JCO.2012.45.2722
- Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies.Cancer Med. 2020; 9: 7964-7978https://doi.org/10.1002/cam4.3428
- Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.Sci Rep. 2020; 10: 1456https://doi.org/10.1038/s41598-020-58498-2
- Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.J Clin Med. 2019; 8https://doi.org/10.3390/jcm8040450
- Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis.Nutrition. 2021; 90111345https://doi.org/10.1016/j.nut.2021.111345
- Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer.Medicine. 2020; 99e19059https://doi.org/10.1097/MD.0000000000019059
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.Eur J Cancer. 2016; 65: 33-42https://doi.org/10.1016/j.ejca.2016.05.031
- Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.JAMA Oncol. 2018; 4: 351-357https://doi.org/10.1001/jamaoncol.2017.4771
- From cachexia to obesity: the role of host metabolism in cancer immunotherapy.Curr Opin Support Palliat Care. 2019; 13: 305-310https://doi.org/10.1097/SPC.0000000000000457
- Obesity, sarcopenia, and outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors.Front Oncol. 2020; 10576314https://doi.org/10.3389/fonc.2020.576314
- The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: a pooled analysis of 4090 cancer patients.Int Immunopharmacol. 2019; 74105745https://doi.org/10.1016/j.intimp.2019.105745
- Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.J Transl Med. 2020; 18: 235https://doi.org/10.1186/s12967-020-02404-x
- Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data.Ann Oncol Off J Eur Soc Med Oncol. 2021; 32: 542-551https://doi.org/10.1016/j.annonc.2020.12.012
- Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.J Immunother cancer. 2020; 8https://doi.org/10.1136/jitc-2020-000821
- Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.J Immunother cancer. 2020; 8https://doi.org/10.1136/jitc-2020-001674
- Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.Cancer Manag Res. 2019; 11: 8201-8207https://doi.org/10.2147/CMAR.S210958
- Cachexia – sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.Lung Cancer. 2020; 143: 19-26https://doi.org/10.1016/j.lungcan.2020.03.003
- Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade.JAMA Netw Open. 2022; 5e220448https://doi.org/10.1001/jamanetworkopen.2022.0448
- Assessment of computed tomography (CT)-Defined muscle and adipose tissue features in relation to short-term outcomes after elective surgery for colorectal cancer: a multicenter approach.Ann Surg Oncol. 2018; 25: 2669-2680https://doi.org/10.1245/s10434-018-6652-x
- Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.J Cancer Res Clin Oncol. 2020; 146: 1217-1225https://doi.org/10.1007/s00432-020-03146-5
- Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study.Sci Rep. 2019; 9: 2447https://doi.org/10.1038/s41598-019-39120-6
- Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma.J Cachexia Sarcopenia Muscle. 2020; 11: 748-755https://doi.org/10.1002/jcsm.12538
- Morphomics predicts response to ipilimumab in patients with stage IV melanoma.J Surg Oncol. 2015; 112: 333-337https://doi.org/10.1002/jso.24003
- The “obesity paradox” may not be a paradox at all.Int J Obes. 2017; 41: 1162-1163https://doi.org/10.1038/ijo.2017.99
- Small steps towards big mediation.in: 5th UK causal inference meeting. Colchester. 2017
- Obesity is associated with improved postoperative overall survival, independent of skeletal muscle mass in lung adenocarcinoma.J Cachexia Sarcopenia Muscle. 2022; 13: 1076-1086